[Hyperfractionated irradiation with cobalt 60 in ORL cancers].
So-called "hyperfractionated" radiotherapy is aimed at obtaining synchronisation of tumour cells and to kill the cells synchronised in this way. The technique has been used now for approximately a year and a half in the treatment of 45 advanced or inoperable squamous carcinomas of the upper respiratory and digestive tract. The initial results are encouraging. Oncological sterilisation of the lesions is obtained at the price of actinic reactions which rapidly disappear, but also tumour necrosis, which indicates the need for review of the protocol.
D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000532:radiotherapy; D008207:Lymphatic Metastasis; D009062:Mouth Neoplasms / Q000532:radiotherapy; D009369:Neoplasms / Q000532:radiotherapy*; D010038:Otorhinolaryngologic Diseases / Q000532:radiotherapy*; D010255:Paranasal Sinus Neoplasms / Q000532:radiotherapy; D010610:Pharyngeal Neoplasms / Q000532:radiotherapy; D011879:Radiotherapy Dosage
D003037:Cobalt Radioisotopes
Irradiation hyperfractionnée au cobalt 60 dans les cancers de la sphère O.R.L.